A Study of SGN-PDL1V in Advanced Solid Tumors

A Study of SGN-PDL1V in Advanced Solid Tumors
Conditions:   Carcinoma, Non-Small-Cell Lung;   Squamous Cell Carcinoma of the Head and Neck;   Esophageal Squamous Cell Carcinoma;   Ovarian Neoplasms;   Melanoma
Intervention:   Drug: SGN-PDL1V
Sponsor:   Seagen Inc.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine